Citi raised the firm’s price target on GE HealthCare (GEHC) to $93 from $89 and keeps a Buy rating on the shares. The company reported a Q2 beat and guidance raise but the stock sold on order book concerns and its commentary about China, the analyst tells investors in a research note. Citi sees a robust product pipeline for GE HealthCare.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- Cautious Outlook for GE Healthcare Technologies: Hold Rating Maintained Amid Market Expectations and Trade Uncertainties
- GE HealthCare Reports Strong Q2 2025 Performance
- GE Healthcare’s Earnings Call Highlights Growth Amid Challenges
- Morning Movers: Wingstop jumps after second quarter report and dividend raise
- GE HealthCare reports Q2 adjusted EPS $1.06, consensus 92c